The strong phlebotomy reduction and hematocrit control data for DISC-3405 in PV significantly de-risks the program. Traders should watch for the upcoming FDA end-of-Phase 2 meeting for selcodebart and initial sickle cell disease data for DISC-3405, both expected by end of 2026, as key catalysts. The stock has historically responded well to positive clinical data (T+20 avg +4.46% on prior directional calls).
Price Chart
Executive Summary
Disc Medicine presented positive initial Phase 2 data for DISC-3405 in polycythemia vera (PV) at SOHO 2026, showing significant phlebotomy reduction and hematocrit control. The company also provided an encore of positive Phase 2 RALLY-MF data for selcodebart in anemia of myelofibrosis. Both programs are advancing toward potential pivotal development, with an FDA end-of-Phase 2 meeting for selcodebart expected by year-end.
Key Facts
- DISC-3405 reduced mean total phlebotomy events from 4.0 to 0.6 per 26 weeks (p<0.0001) in PV patients.
- 61.5% of patients remained phlebotomy-free post-baseline through 26 weeks.
- Mean hematocrit maintained stably <45% through week 26.
- DISC-3405 is the first anti-TMPRSS6 mAb to demonstrate phlebotomy reduction in PV patients.
- Disc plans to provide an update on RESTORE-PV and initial Phase 1b data in sickle cell disease by end of 2026.
- Selcodebart (DISC-0974) positive Phase 2 RALLY-MF data encore presented; FDA end-of-Phase 2 meeting expected by year-end.
- PV affects approximately 150,000 patients in the U.S.
Financial Impact
Positive clinical data for two pipeline programs (DISC-3405 in PV, selcodebart in MF) de-risks pivotal development and supports a multi-billion-dollar peak sales opportunity in a large, underserved PV population (~150K U.S. patients). No financial figures provided.
Risk Factors
- DISC-3405 is still in Phase 2; larger pivotal trials are needed to confirm efficacy and safety.
- Competition from existing PV therapies (phlebotomy, cytoreductive agents) and emerging pipeline candidates.
- Selcodebart's FDA end-of-Phase 2 outcome is uncertain; regulatory path for anemia of MF is not established.
- Clinical-stage biotech with no approved products; capital needs for pivotal trials may require future financing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3359133 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $74.14 $69.18 | ▼ −6.69% | ▼ −6.19% | $64.48 (−13.03%) |
Sep 9, 2026 22d ago | Press Release | $74.14 $69.18 | ▼ −6.69% | ▼ −6.19% | $64.48 (−13.03%) |
Sep 3, 2026 28d ago | Insider Cluster | $79.23 $68.92 | ▲ +13.01% | ▲ +11.80% | $64.48 (+18.62%) |
Sep 2, 2026 29d ago | 144 | $79.37 $70.06 | ▼ −11.73% | ▼ −10.58% | $64.48 (−18.76%) |
Aug 27, 2026 5w ago | Insider Cluster | $82.55 $79.37 | ▼ −3.85% | ▼ −4.12% | $64.48 (−21.89%) |
Aug 18, 2026 6w ago | Insider Cluster | $80.32 $82.67 | ▲ +2.93% | ▲ +3.31% | $64.48 (−19.72%) |
Aug 14, 2026 6w ago | Insider Cluster | $80.05 $80.94 | ▲ +1.11% | ▲ +2.30% | $64.48 (−19.45%) |
Jul 30, 2026 9w ago | 8-K | $79.21 $77.44 | ▼ −2.23% | ▼ −5.86% | $64.48 (−18.60%) |
Jul 30, 2026 9w ago | Press Release | $79.21 $77.44 | ▼ −2.23% | ▼ −5.86% | $64.48 (−18.60%) |
Jul 14, 2026 11w ago | Insider Cluster | $76.02 $74.32 | ▼ −2.24% | ▼ −1.26% | $64.48 (−15.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access